Abstract
The research and development of molecular biomarkers in prostate cancer has grown rapidly in the last decade and has been applied clinically. For diagnosis, assays combining various molecular biomarkers have been developed in addition to PSA. For treatment, the development of testing techniques such as next-generation sequencing and new therapeutic agents such as PARP inhibitors for patients with metastatic castration-resistant prostate cancer have been developed, and treatment options are available. Therefore, we will focus on the molecular biomarkers described in the major guidelines, as well as those expected in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Biomarkers in Cancer Detection and Monitoring of Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
